Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDC224
- Development stage
- Preclinical
- Lead developer
- Prestige Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
IDC224 is a preclinical-stage innovative drug candidate being developed by Prestige Biopharma (PBK) for the treatment of breast cancer. The candidate is developed using PBK's proprietary subcutaneous (SC) platform technology, which is designed to enable the subcutaneous administration of monoclonal antibodies that are traditionally delivered via intravenous infusion. This platform aims to improve patient convenience and reduce the burden on healthcare infrastructure by allowing for faster and easier drug delivery. As of current pipeline reports, IDC224 is in the Proof of Concept (PoC) phase. While it is categorized within the company's innovative antibody pipeline, its specific biological target and detailed mechanism of action have not been publicly disclosed.
- Other names
- IDC224-PBKIDC-224-PBKIDC 224-PBKsubcutaneous platform antibody
Beyond the preview
Go deeper on IDC224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDC224.